For the millions of adults who have failed multiple antidepressants or remain trapped in PTSD cycles, the promise of psychedelic medicine is not abstract—it is urgent. What distinguishes this moment from earlier psychedelic research eras is the volume and rigor of clinical data now available, and this comprehensive review in Expert Opinion on Pharmacotherapy synthesizes exactly where that evidence stands, and where the gaps remain formidable.

The review draws on Phase II and III trial data across six distinct compounds—ketamine/esketamine, MDMA, psilocybin, LSD, DMT/5-MeO-DMT, and ibogaine—applied to treatment-resistant depression, major depressive disorder, PTSD, anxiety disorders, and substance use disorders. A critical through-line across the compounds is the pattern of rapid onset with sustained effect, a pharmacological signature that fundamentally differs from conventional SSRIs requiring weeks to act. The authors also map regulatory trajectories across U.S., EU, and international jurisdictions, noting that no single approval framework cleanly accommodates a therapy requiring specialist-supervised psychotherapy integration alongside drug administration.

This review arrives at an inflection point where clinical enthusiasm is running measurably ahead of the infrastructure needed to deliver these therapies responsibly. The FDA's 2024 rejection of MDMA-assisted therapy for PTSD—citing data quality and study blinding concerns—is a sobering reminder that late-stage trial results do not automatically translate into approvals. Esketamine remains the only approved psychedelic-adjacent compound with a current clinical footprint, and its restricted REMS dispensing model offers the most realistic preview of how future psychedelic drugs might be regulated: effective but structurally difficult to scale. The review's identification of workforce training, long-term safety surveillance, and equitable access as unresolved challenges reflects genuine structural bottlenecks, not theoretical concerns. For health-conscious adults tracking this space, the evidence base is legitimately compelling but remains insufficient to support broad clinical rollout. This is confirmatory and synthesizing work rather than paradigm-shifting, but it is among the most comprehensive regulatory and clinical mappings of the field to date.